Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2

SOL #: DARPA-PS-26-124Solicitation

Overview

Buyer

DEPT OF DEFENSE
Defense Advanced Research Projects Agency (Darpa)
DEF ADVANCED RESEARCH PROJECTS AGCY
ARLINGTON, VA, 222032114, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

National Defense R&D Services; Department Of Defense Military; Applied Research (AC12)

Set Aside

No set aside specified

Timeline

1
Posted
May 27, 2026
2
Submission Deadline
Jun 24, 2026, 4:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Advanced Research Projects Agency (DARPA), specifically its Biological Technologies Office (BTO), has issued a Solicitation for the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. This initiative seeks proposals for Phase 1 ONLY of Task Area (TA)-1 and/or TA-2 to develop a transformative, end-to-end blood analog system (BAS) for far-forward trauma care. The goal is to create a fieldable, usable, and scalable capability equivalent or superior to stored whole blood, eliminating reliance on cold chain and donor logistics.

Scope of Work

The RAPIID program aims to develop a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines. Technologies are expected to advance to Technology Readiness Level (TRL) 7 for components and TRL 8 for devices/diagnostics.

  • TA-1: Individual Blood Analog Components – Focuses on developing shelf-stable components such as oxygen carriers, platelet-derived products, or dried plasma. Proposals for oxygen carriers or platelet-like particles must also include a TA-2 detection technology.
  • TA-2: Blood Analog System (BAS) Fielding Technologies – Concentrates on developing delivery formats and point-of-care diagnostics to support far-forward use, transfusion decisions, and analysis of blood analog effects.

Contract Details & Timeline

  • Contract Type: Other Transaction (OT) for Prototype.
  • Period of Performance: Phase 1 is 12 months. Phase 2 is an option for 24 months.
  • Questions Due: June 3, 2026, 4:00 PM ET.
  • Proposal Due: June 24, 2026, 4:00 PM ET.
  • Published Date: May 27, 2026.

Eligibility & Evaluation

  • Eligibility: Open to large and small businesses, nontraditional defense contractors, and research institutions. Federal Funded Research and Development Centers (FFRDCs), University Affiliated Research Centers (UARCs), and Government Entities are not eligible. Organizations awarded TA-1/TA-2 are not eligible for TA-3/TA-4 awards.
  • Set-Aside: None specified.
  • Evaluation Criteria: Proposals will be assessed based on Overall Scientific and Technical Merit, Potential Contribution and Relevance to DARPA Mission, and Cost and Schedule Realism.

Submission Requirements & Notes

Proposers must submit full proposals via DARPA’s Broad Agency Announcement Tool (BAAT). Mandatory attachments include a Technical and Management Proposal (Attachment A), Cost Proposal (Attachment B) using the DARPA Standard Cost Proposal Spreadsheet (Attachment C), a Task Description Document (Attachment E), and a Schedule of Milestones and Payments (Attachment F). Bidders must also understand and comply with the Controlled Unclassified Information (CUI) Guide (Attachment G) and review the Model Other Transaction for Prototype Agreement (Attachment D). Proposers must have a Unique Identity ID and be registered in SAM.gov.

People

Points of Contact

BAA CoordinatorPRIMARY

Files

Files

Download
Download
Download
Download
Download
Download
Download
Download

Versions

Version 1Viewing
Solicitation
Posted: May 27, 2026
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2 | GovScope